Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT05481476 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neoplasms

Interventions

DRUG: Surufatinib
DRUG: Sintilimab
DRUG: AG

Sponsor

Sun Yat-sen University